Safety of Tumour Necrosis Factor-α Antagonists

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Drug Safety

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00002018-200427050-00003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid Arthritis

  2004cited by this paper
• Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial

  2003cited by this paper
• Polymicrobial septic arthritis in a patient with Wilson’s disease

  2003cited by this paper
• Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

  2003cited by this paper
• Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.

  2003cited by this paper
• Evaluation of free and peptide bound collagen crosslink excretion in different skeletal diseases

  2003cited by this paper
• Pregnancy and exposure to infliximab (anti‐tumor necrosis factor‐alpha monoclonal antibody)

  2003cited by this paper
• Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma.

  2003cited by this paper
• Evolving concepts of rheumatoid arthritis

  2003cited by this paper
• Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.

  2003cited by this paper
• Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

  2003cited by this paper
• Rheumatoid vasculitis following influenza vaccination.

  2003cited by this paper
• Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

  2003cited by this paper
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

  2003cited by this paper
• Infliximab in the treatment of an HIV positive patient with Reiter's syndrome.

  2003cited by this paper
• Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist

  2003cited by this paper
• The use of etanercept and other tumor necrosis factor-alpha blockers in infertility: it's time to get serious.

  2003cited by this paper
• Infectious complications of biologic treatments of rheumatoid arthritis

  2003cited by this paper
• Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection.

  2003cited by this paper
• Viral pneumonia as a serious complication of etanercept therapy.

  2002cited by this paper
• Kinetics of cytokine expression in mice with invasive aspergillosis: lethal infection and protection.

  2002cited by this paper
• Anti-implantation effects of indomethacin and celecoxib in rats.

  2002cited by this paper
• What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.

  2002cited by this paper
• Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents

  2002cited by this paper
• Inflammatory mediators and the failing heart: past, present, and the foreseeable future.

  2002cited by this paper
• Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.

  2002cited by this paper
• Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.

  2002cited by this paper
• Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

  2002cited by this paper
• Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis

  2002cited by this paper
• Drug-induced systemic lupus erythematosus associated with etanercept therapy.

  2002cited by this paper
• Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.

  2002cited by this paper
• Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab.

  2002cited by this paper
• Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)

  2002cited by this paper
• The mode of action of cytokine inhibitors.

  2002cited by this paper
• Tuberculosis and treatment with infliximab.

  2002cited by this paper
• Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH

  2002cited by this paper
• Vaccination and rheumatoid arthritis

  2002cited by this paper
• Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus.

  2002cited by this paper
• A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.

  2002cited by this paper
• Binding and functional comparisons of two types of tumor necrosis factor antagonists.

  2002cited by this paper
• Prediction of Pregnancy in Infertile Women with Endometriosis

  2002cited by this paper
• Drug-induced systemic lupus erythematosus and TNF-α blockers

  2002cited by this paper
• Cytokine pathways and joint inflammation in rheumatoid arthritis.

  2001cited by this paper
• Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

  2001cited by this paper
• Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein.

  2001cited by this paper
• Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway.

  2001cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

  2001cited by this paper
• Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety.

  2001cited by this paper
• Successful Ovulation Induction, Conception, and Normal Delivery after Chronic Therapy with Etanercept: A Recombinant Fusion Anti‐cytokine Treatment for Rheumatoid Arthritis

  2001cited by this paper
• Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis.

  2000cited by this paper
• Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

  2000cited by this paper
• The Pharmacokinetics of Etanercept in Healthy Volunteers

  2000cited by this paper
• A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

  2000cited by this paper
• Effect of Patient Adherence to Antiretroviral Therapy on CD4+ Cell Count, HIV-1 RNA, and Serum Concentrations of Tumor Necrosis Factor and its Soluble Receptors

  2000cited by this paper
• Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

  2000cited by this paper
• Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

  2000cited by this paper
• HBV‐specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro‐ and anti‐inflammatory cytokines

  1999cited by this paper
• Evaluation of Nonspecific Immunity and Plasma Levels of Interferon-γ, Interleukin-6 and Tumor Necrosis Factor-α in Preeclampsia

  1999cited by this paper
• Tumor necrosis factor during pregnancy and at the onset of labor and spontaneous abortion.

  1999cited by this paper
• Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

  1999cited by this paper
• Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

  1998cited by this paper
• Tumour necrosis factor-alpha induces cyclo-oxygenase-2 gene expression in first trimester trophoblasts: suppression by glucocorticoids and NSAIDs.

  1997cited by this paper
• Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2

  1996cited by this paper
• Basic mechanisms in heart failure: the cytokine hypothesis.

  1996cited by this paper
• Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1.

  1996cited by this paper
• Regulation of COX-2 gene expression in rat uterus in vivo and in vitro.

  1996cited by this paper
• Mortality from cancer in patients with rheumatoid arthritis.

  1995cited by this paper
• Acute sero-positive rheumatoid arthritis occurring after hepatitis vaccination.

  1994cited by this paper
• Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.

  1993cited by this paper
• Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

  1993cited by this paper
• Anti—tumor necrosis factor therapy abrogates autoimmune demyelination

  1991cited by this paper
• Cytokines modulate preimplantation development and pregnancy.

  1991cited by this paper
• Molecular cloning and expression of a receptor for human tumor necrosis factor.

  1990cited by this paper
• Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences.

  1990cited by this paper
• Purified blood monocytes from HIV 1-infected patients induce high levels of TNFα and IL-1

  1989cited by this paper
• Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice

  1989cited by this paper
• Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum.

  1988cited by this paper
• Tumor necrosis factor and HIV P24 antigen levels in serum of HIV-infected populations.

  1988cited by this paper
• Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon.

  1988cited by this paper
• Tumour necrosis factors α and β inhibit virus replication and synergize with interferons

  1986cited by this paper
• Cancer morbidity in rheumatoid arthritis.

  1984cited by this paper
• Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis.

  1978cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Tailored Treatments: Utilizing Anti-TNFs for Ankylosing Spondylitis and Essential Thrombocytosis

  2025cites this paper
• Chronic TNF exposure induces glucocorticoid‐like immunosuppression in the alveolar macrophages of aged mice that enhances their susceptibility to pneumonia

  2024cites this paper
• Case report: Crescentic IgA nephropathy with anti‐neutrophil cytoplasmic antibodies, in a patient on golimumab

  2024cites this paper
• TNF-alpha inhibitors in organ transplant recipients: a retrospective cohort study

  2024cites this paper
• Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

  2023cites this paper
• Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment

  2023cites this paper
• Intrathecal Pseudodelivery of Drugs in the Therapy of Neurodegenerative Diseases: Rationale, Basis and Potential Applications

  2023cites this paper
• Penta-o-galloyl-beta-d-Glucose (PGG) inhibits inflammation in human rheumatoid arthritis synovial fibroblasts and rat adjuvant-induced arthritis model

  2022cites this paper
• Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease

  2022cites this paper
• Infliximab‐induced seizures in a patient with Crohn’s disease: a case report

  2021cites this paper
• Rheumatoid meningitis: A systematic review and meta‐analysis

  2021cites this paper
• Risk factors and prevention of Pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases.

  2020cites this paper
• Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview

  2020cites this paper
• Biologics in Wound Management

  2020cites this paper
• The Association of TNF-Alpha Inhibitors and Development of IgA Nephropathy in Patients with Rheumatoid Arthritis and Diabetes

  2020cites this paper
• Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

  2018cites this paper
• ANCA‐positive crescentic glomerulonephritis in a patient with rheumatoid arthritis treated with anti‐tumor necrosis factor alpha

  2017cites this paper
• Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial

  2017cites this paper
• Fullerenes and their derivatives as inhibitors of tumor necrosis factor-α with highly promoted affinities

  2016cites this paper
• Boswellia serrata for Arthritis Relief: A Journey from Frankincense to Aapin and 5-Loxin

  2016cites this paper
• Chapter 8 – Etanercept

  2016cites this paper
• Chapter 10 – Adalimumab

  2016cites this paper
• Chapter 9 – Infliximab

  2016cites this paper
• Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C.

  2016cites this paper
• Regulation of Transforming Growth Factor β–Activated Kinase Activation by Epigallocatechin‐3‐Gallate in Rheumatoid Arthritis Synovial Fibroblasts: Suppression of K63‐Linked Autoubiquitination of Tumor Necrosis Factor Receptor–Associated Factor 6

  2015cites this paper
• Efficacy and Safety of Celecoxib in Chinese Patients with Ankylosing Spondylitis: A 6-Week Randomized, Double-Blinded Study with 6-Week Open-Label Extension Treatment

  2014cites this paper
• Suppression of Collagen-Induced Arthritis in Mice by Anti-Collagen Antibody Fab Fragments

  2014cites this paper
• Infliximab-associated autoimmune limbic encephalitis: a case report

  2014cites this paper
• Adalimumab (TNFα Inhibitor) Therapy Exacerbates IgA Glomerulonephritis Acute Renal Injury and Induces Lupus Autoantibodies in a Psoriasis Patient

  2013cites this paper
• Necrotizing fasciitis in a pediatric patient treated with etanercept and cyclosporine for macrophage activation syndrome

  2013cites this paper
• Pneumocystisjirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors

  2012cites this paper
• Adult-Onset Still’s Disease

  2012cites this paper
• Crohn’s Disease

  2012cites this paper
• Etanercept: efficacy and safety for approved indications

  2012cites this paper
• Spotlight on Infliximab in Crohn Disease and Rheumatoid Arthritis

  2012cites this paper
• Common anti-infective prophylaxis and vaccinations in autoimmune inflammatory rheumatic diseases

  2012cites this paper
• Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis

  2012cites this paper
• Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case–control study of 17 patients

  2012cites this paper
• Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment.

  2012cites this paper
• Biologic Therapy of Crohn’s Disease: Infliximab

  2012cites this paper
• Experience of monitoring subcutaneous biological treatment (adalimumab) by nurses in chronic inflammatory diseases

  2011cites this paper
• Iatrogenic effects of biologics for psoriasis.

  2011cites this paper
• Infliximab-related seizures: a first case study

  2011cites this paper
• INFLIXIMAB (REMICADE): POSSIBILITIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS

  2011cites this paper
• Infliximab- and azathioprine-related severe neutropenia and thrombocytopenia in a case with Crohn's disease.

  2011cites this paper
• Infl iximab: 12 years of experience

  2011cites this paper
• [Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients].

  2011cites this paper
• Immobilization of a human epidermal growth factor receptor 2 mimotope-derived synthetic peptide on Au and its potential application for detection of herceptin in human serum by quartz crystal microbalance.

  2011cites this paper
• [Experience of monitoring subcutaneous biological treatment (adalimumab) by nurses in chronic inflammatory diseases].

  2011cites this paper
• Infliximab: 12 years of experience

  2011cites this paper
• Consensus Statement of the Spanish Society of Rheumatology on Risk Management of Biologic Therapy in Rheumatic Patients

  2011cites this paper
• Safety profile of IBD: lymphoma risks.

  2010cites this paper
• Modelling the Time to Onset of Adverse Reactions with Parametric Survival Distributions

  2010cites this paper
• Permanent renal loss following tumor necrosis factor α antagonists for arthritis

  2010cites this paper
• Neurological adverse events associated with anti-tumor necrosis factor alpha treatment

  2010cites this paper
• Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis

  2010cites this paper
• Cautionary note: a possible association between oral squamous cell carcinoma and tumor necrosis factor antagonists; need for oral screening.

  2010cites this paper
• Безопасность применения генно-инженерных биологических препаратов при ревматоидном артрите

  2010cites this paper
• Suppression of antibody‐mediated arthritis in mice by Fab fragments of the mediating antibodies

  2010cites this paper
• [Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis].

  2010cites this paper
• Innovative uses of tumor necrosis factor alpha inhibitors.

  2010cites this paper
• Pregnancy and Systemic Lupus Erythematosus: Review of Clinical Features and Outcome of 51 Pregnancies at a Single Institution

  2010cites this paper
• Terapias biológicas en la enfermedad inflamatoria intestinal: presente y futuro

  2010cites this paper
• Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease

  2010cites this paper
• Safety profile of IBD: lymphoma risks.

  2009cites this paper
• European S3‐Guidelines on the systemic treatment of psoriasis vulgaris

  2009cites this paper
• Molecularly Targeted Therapies for Dysimmune Neuropathies

  2009cites this paper
• Incidence and nature of infectious disease in patients treated with anti-TNF agents.

  2009cites this paper
• Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients.

  2009cites this paper
• Incidence and prognosis of renal diseases and measurement of renal function in patients with rheumatoid arthritis

  2009cites this paper
• Les anticorps monoclonaux : une avancée thérapeutique récente et majeure

  2009cites this paper
• Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients.

  2009cites this paper
• Poor reporting of search strategy and conflict of interest in over 250 narrative and systematic reviews of two biologic agents in arthritis: a systematic review.

  2009cites this paper
• Current treatments of chronic immune‐mediated demyelinating polyneuropathies

  2009cites this paper
• Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease

  2008cites this paper
• Regulação da resposta imune e endometriose

  2008cites this paper
• N-of-1 trials of expensive biological therapies: a third way?

  2008cites this paper
• Es necesario el control de la psoriasis a largo plazo

  2008cites this paper
• Perspectives in pharmacological management of Graves’ hyperthyroidism and orbitopathy

  2008cites this paper
• Minimizing infliximab toxicity in the treatment of inflammatory bowel disease.

  2008cites this paper
• 37 - Drugs that act on the immune system: Cytokines and monoclonal antibodies

  2007cites this paper
• Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges

  2007cites this paper
• Etanercept: a review of its use in the management of ankylosing spondylitis and psoriatic arthritis.

  2007cites this paper
• The Use of Biologics and Other Immunosuppressants in the Treatment of Common Inflammatory Diseases in Neuro-ophthalmology

  2007cites this paper
• Guillain–Barré syndrome in a patient receiving anti-tumour necrosis factor α for rheumatoid arthritis: a case report and discussion of literature

  2007cites this paper
• Etanercept: a review of its use in the management of rheumatoid arthritis.

  2007cites this paper
• Optic neuritis occurring with anti-tumour necrosis factor α therapy

  2007cites this paper
• Padrões de resposta imune em pacientes com endometriose

  2007cites this paper
• Complications of anti-TNF therapies

  2007cites this paper
• The safety of etanercept for the treatment of plaque psoriasis

  2007influential citation
• American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

  2007cites this paper
• Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis

  2007cites this paper
• Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis

  2007cites this paper
• Atypical carcinoid tumor of the thymus with ectopic ACTH production developed during the course of etanercept treatment—case report

  2007cites this paper
• Traitement par etanercept des polyarthrites rhumatoïdes et des spondylarthropathies à la posologie de 25 mg par semaine

  2007cites this paper
• Infliximab Treatment for Ocular and Extraocular Manifestations of Behçet's Disease

  2007cites this paper
• The impact of autoimmune disorders and adverse pregnancy outcome.

  2007cites this paper
• Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.

  2007cites this paper
• The management of fistulizing oral Crohn's disease with infliximab.

  2007cites this paper
• Review article: reproduction in the patient with inflammatory bowel disease

  2007cites this paper